Cover Image
市場調查報告書

T細胞淋巴瘤的開發中產品分析

T-Cell Lymphomas - Pipeline Review, H2 2014

出版商 Global Markets Direct 商品編碼 213075
出版日期 內容資訊 英文 143 Pages
訂單完成後即時交付
價格
Back to Top
T細胞淋巴瘤的開發中產品分析 T-Cell Lymphomas - Pipeline Review, H2 2014
出版日期: 2014年10月31日 內容資訊: 英文 143 Pages
簡介

T細胞淋巴瘤是人體免疫系統的部分淋巴系統發生的癌症。主要的症狀有淋巴結腫瘤及咳嗽、胸痛或呼吸困難、盜汗或隨之而來的倦怠感、食欲不振等。主要治療法有化療和放射治療等。

本報告提供全球各國治療T細胞淋巴瘤用的開發中產品之開發情形相關分析,提供產品開發·上市的最新趨勢,及臨床實驗各階段的產品一覽,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

T細胞淋巴瘤概要

治療藥的開發

  • T細胞淋巴瘤開發中產品:概要
  • T細胞淋巴瘤開發中產品:比較分析

各企業開發中的T細胞淋巴瘤治療藥

大學/研究機關研究中的T細胞淋巴瘤治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

T細胞淋巴瘤治療藥:開發中產品一覽(各企業)

T細胞淋巴瘤治療藥:研究中的產品的一覽(大學/研究機關別)

T細胞淋巴瘤治療藥的開發企業

  • Bristol-Myers Squibb Company
  • Kyowa Hakko Kirin
  • Amgen Inc.
  • Seattle Genetics, Inc.
  • Infinity Pharmaceuticals, Inc.
  • 日本化藥
  • 小野藥品工業
  • Celgene Corporation
  • Onyx Pharmaceuticals, Inc.
  • Mundipharma International Limited
  • Pharmacyclics, Inc.
  • Cell Medica Limited
  • Pharma Mar, S.A.
  • Rhizen Pharmaceuticals SA

T細胞淋巴瘤:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 分子類別
  • 各治療分類

藥物簡介

  • mogamulizumab
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • brentuximab vedotin
  • mogamulizumab
  • forodesine hydrochloride
  • plitidepsin
  • lenalidomide
  • CMD-003
  • carfilzomib
  • nivolumab
  • duvelisib
  • BMS-906024
  • AMG-319
  • RP-6530
  • Drugs to Inhibit PDGFR-Beta Receptor for T-Cell Lymphomas
  • PCI-34051
  • NK-314
  • Drug for T-Cell Lymphoma

T細胞淋巴瘤治療藥:開發中產品的最新趨勢

T細胞淋巴瘤治療藥:暫停開發的產品

T細胞淋巴瘤治療藥:中止開發的產品

T細胞淋巴瘤相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿(全10件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC5590IDB

Summary

Global Markets Direct's, 'T-Cell Lymphomas - Pipeline Review, H2 2014', provides an overview of the T-Cell Lymphomas's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for T-Cell Lymphomas, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Lymphomas and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of T-Cell Lymphomas
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for T-Cell Lymphomas and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the T-Cell Lymphomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the T-Cell Lymphomas pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for T-Cell Lymphomas
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding T-Cell Lymphomas pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • T-Cell Lymphomas Overview
  • Therapeutics Development
    • Pipeline Products for T-Cell Lymphomas - Overview
    • Pipeline Products for T-Cell Lymphomas - Comparative Analysis
  • T-Cell Lymphomas - Therapeutics under Development by Companies
  • T-Cell Lymphomas - Therapeutics under Investigation by Universities/Institutes
  • T-Cell Lymphomas - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • T-Cell Lymphomas - Products under Development by Companies
  • T-Cell Lymphomas - Products under Investigation by Universities/Institutes
  • T-Cell Lymphomas - Companies Involved in Therapeutics Development
    • arGEN-X BV
    • Bristol-Myers Squibb Company
    • Celgene Corporation
    • Cell Medica Limited
    • Infinity Pharmaceuticals, Inc.
    • Karyopharm Therapeutics, Inc.
    • Kyowa Hakko Kirin Co., Ltd.
    • Nippon Kayaku Co., Ltd.
    • Novartis AG
    • Ono Pharmaceutical Co., Ltd.
    • Onyx Pharmaceuticals, Inc.
    • Pharma Mar, S.A.
    • Pharmacyclics, Inc.
    • Seattle Genetics, Inc.
    • Sigma-Tau S.p.A.
  • T-Cell Lymphomas - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ARGX-110 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BMS-906024 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • brentuximab vedotin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • carfilzomib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cell Therapy to Target CD38 for cancer - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CMD-003 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs for T-Cell Lymphoma - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Antagonize PDGFR-Beta for T-Cell Lymphomas - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • duvelisib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IDD-003 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lenalidomide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • luminespib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mogamulizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nivolumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NK-314 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PCI-34051 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pegaspargase - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • plitidepsin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • selinexor - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • T-Cell Lymphomas - Recent Pipeline Updates
  • T-Cell Lymphomas - Dormant Projects
  • T-Cell Lymphomas - Discontinued Products
  • T-Cell Lymphomas - Product Development Milestones
    • Featured News & Press Releases
      • Jun 30, 2014: Reapplication Seeking Approval for Additional Indication for ATL of Mogamulizumab
      • Feb 10, 2014: Change to Supplemental Application Seeking Approval of Additional Indication for Mogamulizumab
      • Jan 23, 2014: Infinity Reports Phase 1 Data of IPI-145 at Sixth Annual T-Cell Lymphoma Forum
      • Jul 19, 2013: Application Seeking Approval for Additional Indication for ATL, PTCL and CTCL of Mogamulizumab
      • Jun 24, 2013: Infinity Pharma Reports Phase I Data Showing Encouraging Clinical Activity Of IPI-145 Across Broad Range Of Blood Cancers At 12th ICML
      • Jun 02, 2013: Seattle Genetics Announces Presentation Of Adcetris Clinical Development Programs At ASCO Annual Meeting 2013
      • Jun 02, 2013: Infinity Pharma Reports Presentation Of Updated Phase I Data Of IPI-145 In Chronic Lymphocytic Leukemia At ASCO Annual Meeting
      • May 15, 2013: Infinity Pharma Announces Presentation Of Clinical Data On IPI-145 At ASCO 2013 And 12th International Conference On Malignant Lymphoma
      • Jan 24, 2013: Seattle Genetics And Millennium Initiate Global Phase III Clinical Trial Of Adcetris In Front-line CD30-Expressing Mature T-Cell Lymphoma
      • Dec 10, 2012: Infinity Pharma Reports IPI-145 Phase I Data Showing Clinical Activity In B-Cell And T-Cell Malignancies At ASH Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for T-Cell Lymphomas, H2 2014
  • Number of Products under Development for T-Cell Lymphomas - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Late Stage Development, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Products under Investigation by Universities/Institutes, H2 2014
  • T-Cell Lymphomas - Pipeline by arGEN-X BV, H2 2014
  • T-Cell Lymphomas - Pipeline by Bristol-Myers Squibb Company, H2 2014
  • T-Cell Lymphomas - Pipeline by Celgene Corporation, H2 2014
  • T-Cell Lymphomas - Pipeline by Cell Medica Limited, H2 2014
  • T-Cell Lymphomas - Pipeline by Infinity Pharmaceuticals, Inc., H2 2014
  • T-Cell Lymphomas - Pipeline by Karyopharm Therapeutics, Inc., H2 2014
  • T-Cell Lymphomas - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2014
  • T-Cell Lymphomas - Pipeline by Nippon Kayaku Co., Ltd., H2 2014
  • T-Cell Lymphomas - Pipeline by Novartis AG, H2 2014
  • T-Cell Lymphomas - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014
  • T-Cell Lymphomas - Pipeline by Onyx Pharmaceuticals, Inc., H2 2014
  • T-Cell Lymphomas - Pipeline by Pharma Mar, S.A., H2 2014
  • T-Cell Lymphomas - Pipeline by Pharmacyclics, Inc., H2 2014
  • T-Cell Lymphomas - Pipeline by Seattle Genetics, Inc., H2 2014
  • T-Cell Lymphomas - Pipeline by Sigma-Tau S.p.A., H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • T-Cell Lymphomas Therapeutics - Recent Pipeline Updates, H2 2014
  • T-Cell Lymphomas - Dormant Projects, H2 2014
  • T-Cell Lymphomas - Discontinued Products, H2 2014

List of Figures

  • Number of Products under Development for T-Cell Lymphomas, H2 2014
  • Number of Products under Development for T-Cell Lymphomas - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Late Stage Development, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Products, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Targets, H2 2014
  • Number of Products by Stage and Top 10 Targets, H2 2014
  • Number of Products by Top 10 Mechanism of Actions, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014
  • Number of Products by Top 10 Routes of Administration, H2 2014
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2014
  • Number of Products by Top 10 Molecule Types, H2 2014
  • Number of Products by Stage and Top 10 Molecule Types, H2 2014
Back to Top